Rituximab and autologous stem cell transplantation for malignant lymphoma after liver transplantation

Solid organ transplantation (SOT) followed by hematopoietic cell transplantation (HCT) has been used to treat a single disease with multiorgan involvement or 2 separate diseases, the first requiring SOT and the second often a possible complication of SOT. Results of such serial transplants have been reported sporadically in the literature, usually as single case studies. Thirteen autologous and 27 allogeneic HCTs after SOT published previously are summarized. A more detailed review is provided for an additional 16 patients transplanted at a single institution, 8 of whom had autologous and 8 of whom had allogeneic HCT after SOT. Five of 8 autologous transplant recipients are alive a median of 4.6 years after HCT. Four of 8 allogeneic HCT recipients are alive a median of 8.7 years after HCT. In carefully selected patients, HCT after SOT is feasible and associated with a low incidence of either solid organ or hematopoietic cell rejection.

show abstract

Hematopoietic Cell Transplantation after Solid Organ Transplantation

Doney

Mielcarek

Stewart

et al. 2015

Biology of Blood and Marrow Transplantation

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Rituximab and autologous stem cell transplantation for malignant lymphoma after liver transplantation

Abstract: Post transplant lymphoproliferative disorders (PTLDs) occur in 0.7-32% of solid organ transplant (SOT) patients.

Cited by 1 publication

References 9 publications

Hematopoietic Cell Transplantation after Solid Organ Transplantation

Hematopoietic Cell Transplantation after Solid Organ Transplantation

Contact Info

Product

Resources

About